#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Biofilms
2-1	4-12	Biofilms	abstract	new	coref	7-3

#Text=As mentioned above , the most common problems of stents are due to their clogging due to the formation of biofilm and adhesion of biological substances that pass through the stent .
3-1	13-15	As	_	_	_	_
3-2	16-25	mentioned	_	_	_	_
3-3	26-31	above	_	_	_	_
3-4	32-33	,	_	_	_	_
3-5	34-37	the	abstract[3]	new[3]	_	_
3-6	38-42	most	abstract[3]	new[3]	_	_
3-7	43-49	common	abstract[3]	new[3]	_	_
3-8	50-58	problems	abstract[3]	new[3]	_	_
3-9	59-61	of	abstract[3]	new[3]	_	_
3-10	62-68	stents	abstract[3]|object	new[3]|new	ana	3-14
3-11	69-72	are	_	_	_	_
3-12	73-76	due	_	_	_	_
3-13	77-79	to	_	_	_	_
3-14	80-85	their	object|abstract[6]	giv|new[6]	coref|coref	16-11|16-11
3-15	86-94	clogging	abstract[6]	new[6]	_	_
3-16	95-98	due	abstract[6]	new[6]	_	_
3-17	99-101	to	_	_	_	_
3-18	102-105	the	abstract[7]	new[7]	_	_
3-19	106-115	formation	abstract[7]	new[7]	_	_
3-20	116-118	of	abstract[7]	new[7]	_	_
3-21	119-126	biofilm	abstract[7]|substance	new[7]|new	coref	4-1
3-22	127-130	and	abstract[7]	new[7]	_	_
3-23	131-139	adhesion	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-24	140-142	of	abstract[7]|abstract[9]	new[7]|new[9]	_	_
3-25	143-153	biological	abstract[7]|abstract[9]|substance[10]	new[7]|new[9]|new[10]	coref	9-11[45_10]
3-26	154-164	substances	abstract[7]|abstract[9]|substance[10]	new[7]|new[9]|new[10]	_	_
3-27	165-169	that	_	_	_	_
3-28	170-174	pass	_	_	_	_
3-29	175-182	through	_	_	_	_
3-30	183-186	the	object[11]	new[11]	_	_
3-31	187-192	stent	object[11]	new[11]	_	_
3-32	193-194	.	_	_	_	_

#Text=Biofilm represents the most widespread way of microbial growth in nature and is critical for the development of clinical infections .
4-1	195-202	Biofilm	substance	giv	ana	5-1
4-2	203-213	represents	_	_	_	_
4-3	214-217	the	abstract[13]	new[13]	_	_
4-4	218-222	most	abstract[13]	new[13]	_	_
4-5	223-233	widespread	abstract[13]	new[13]	_	_
4-6	234-237	way	abstract[13]	new[13]	_	_
4-7	238-240	of	abstract[13]	new[13]	_	_
4-8	241-250	microbial	abstract[13]|abstract[14]	new[13]|new[14]	coref	17-20[81_14]
4-9	251-257	growth	abstract[13]|abstract[14]	new[13]|new[14]	_	_
4-10	258-260	in	abstract[13]|abstract[14]	new[13]|new[14]	_	_
4-11	261-267	nature	abstract[13]|abstract[14]|abstract	new[13]|new[14]|new	_	_
4-12	268-271	and	_	_	_	_
4-13	272-274	is	_	_	_	_
4-14	275-283	critical	_	_	_	_
4-15	284-287	for	_	_	_	_
4-16	288-291	the	event[16]	new[16]	_	_
4-17	292-303	development	event[16]	new[16]	_	_
4-18	304-306	of	event[16]	new[16]	_	_
4-19	307-315	clinical	event[16]|abstract[17]	new[16]|new[17]	coref	20-9[101_17]
4-20	316-326	infections	event[16]|abstract[17]	new[16]|new[17]	_	_
4-21	327-328	.	_	_	_	_

#Text=It is produced by bacteria and host products that tend to adhere to different surfaces .
5-1	329-331	It	substance	giv	coref	7-10
5-2	332-334	is	_	_	_	_
5-3	335-343	produced	_	_	_	_
5-4	344-346	by	_	_	_	_
5-5	347-355	bacteria	animal	new	coref	7-27
5-6	356-359	and	_	_	_	_
5-7	360-364	host	_	_	_	_
5-8	365-373	products	abstract	new	ana	6-1
5-9	374-378	that	_	_	_	_
5-10	379-383	tend	_	_	_	_
5-11	384-386	to	_	_	_	_
5-12	387-393	adhere	_	_	_	_
5-13	394-396	to	_	_	_	_
5-14	397-406	different	place[21]	new[21]	_	_
5-15	407-415	surfaces	place[21]	new[21]	_	_
5-16	416-417	.	_	_	_	_

#Text=They create huge colonies known as biofilms .
6-1	418-422	They	abstract	giv	coref	11-13[58_0]
6-2	423-429	create	_	_	_	_
6-3	430-434	huge	place[23]	new[23]	_	_
6-4	435-443	colonies	place[23]	new[23]	_	_
6-5	444-449	known	_	_	_	_
6-6	450-452	as	_	_	_	_
6-7	453-461	biofilms	_	_	_	_
6-8	462-463	.	_	_	_	_

#Text=Existence in biofilms is for them more advantageous because biofilm provides protection for their cells , maintains a homeostasis , and creates a barrier that isolates bacteria from the surroundings .
7-1	464-473	Existence	abstract[24]	new[24]	_	_
7-2	474-476	in	abstract[24]	new[24]	_	_
7-3	477-485	biofilms	abstract[24]|substance	new[24]|giv	ana	7-6
7-4	486-488	is	_	_	_	_
7-5	489-492	for	_	_	_	_
7-6	493-497	them	substance	giv	ana	7-14
7-7	498-502	more	_	_	_	_
7-8	503-515	advantageous	_	_	_	_
7-9	516-523	because	_	_	_	_
7-10	524-531	biofilm	substance	giv	coref	9-6
7-11	532-540	provides	_	_	_	_
7-12	541-551	protection	abstract	new	_	_
7-13	552-555	for	_	_	_	_
7-14	556-561	their	substance|object[30]	giv|new[30]	coref|coref|coref|coref	9-3[43_30]|15-1|9-3[43_30]|15-1
7-15	562-567	cells	object[30]	new[30]	_	_
7-16	568-569	,	_	_	_	_
7-17	570-579	maintains	_	_	_	_
7-18	580-581	a	abstract[31]	new[31]	_	_
7-19	582-593	homeostasis	abstract[31]	new[31]	_	_
7-20	594-595	,	_	_	_	_
7-21	596-599	and	_	_	_	_
7-22	600-607	creates	_	_	_	_
7-23	608-609	a	object[32]	new[32]	_	_
7-24	610-617	barrier	object[32]	new[32]	_	_
7-25	618-622	that	_	_	_	_
7-26	623-631	isolates	_	_	_	_
7-27	632-640	bacteria	animal	giv	coref	8-6[36_0]
7-28	641-645	from	_	_	_	_
7-29	646-649	the	place[34]	new[34]	_	_
7-30	650-662	surroundings	place[34]	new[34]	_	_
7-31	663-664	.	_	_	_	_

#Text=There is extensive communication between bacteria and the effective horizontal transfer of resistance and virulence genes that make bacteria very resistant .
8-1	665-670	There	_	_	_	_
8-2	671-673	is	_	_	_	_
8-3	674-683	extensive	abstract[35]	new[35]	_	_
8-4	684-697	communication	abstract[35]	new[35]	_	_
8-5	698-705	between	abstract[35]	new[35]	_	_
8-6	706-714	bacteria	abstract[35]|animal[36]	new[35]|giv[36]	coref	8-19[0_36]
8-7	715-718	and	abstract[35]|animal[36]	new[35]|giv[36]	_	_
8-8	719-722	the	abstract[35]|animal[36]|event[37]	new[35]|giv[36]|new[37]	_	_
8-9	723-732	effective	abstract[35]|animal[36]|event[37]	new[35]|giv[36]|new[37]	_	_
8-10	733-743	horizontal	abstract[35]|animal[36]|event[37]	new[35]|giv[36]|new[37]	_	_
8-11	744-752	transfer	abstract[35]|animal[36]|event[37]	new[35]|giv[36]|new[37]	_	_
8-12	753-755	of	abstract[35]|animal[36]|event[37]	new[35]|giv[36]|new[37]	_	_
8-13	756-766	resistance	abstract[35]|animal[36]|event[37]|abstract	new[35]|giv[36]|new[37]|new	coref	18-1[85_0]
8-14	767-770	and	abstract[35]|animal[36]|event[37]	new[35]|giv[36]|new[37]	_	_
8-15	771-780	virulence	abstract[35]|animal[36]|event[37]|abstract|abstract[40]	new[35]|giv[36]|new[37]|new|new[40]	_	_
8-16	781-786	genes	abstract[35]|animal[36]|event[37]|abstract[40]	new[35]|giv[36]|new[37]|new[40]	_	_
8-17	787-791	that	_	_	_	_
8-18	792-796	make	_	_	_	_
8-19	797-805	bacteria	animal	giv	coref	9-3
8-20	806-810	very	_	_	_	_
8-21	811-820	resistant	_	_	_	_
8-22	821-822	.	_	_	_	_

#Text=Thus , bacteria cells in biofilm are more resistant to toxic substances , UV radiation , mechanical damage , bacteriophages , or predators .
9-1	823-827	Thus	_	_	_	_
9-2	828-829	,	_	_	_	_
9-3	830-838	bacteria	animal|object[43]	giv|giv[43]	coref|coref|coref|coref	11-11|19-1[92_43]|11-11|19-1[92_43]
9-4	839-844	cells	object[43]	giv[43]	_	_
9-5	845-847	in	object[43]	giv[43]	_	_
9-6	848-855	biofilm	object[43]|substance	giv[43]|giv	coref	11-17[59_0]
9-7	856-859	are	_	_	_	_
9-8	860-864	more	_	_	_	_
9-9	865-874	resistant	_	_	_	_
9-10	875-877	to	_	_	_	_
9-11	878-883	toxic	substance[45]	giv[45]	coref	19-11[95_45]
9-12	884-894	substances	substance[45]	giv[45]	_	_
9-13	895-896	,	substance[45]	giv[45]	_	_
9-14	897-899	UV	substance[45]|place|substance[47]	giv[45]|new|new[47]	_	_
9-15	900-909	radiation	substance[45]|substance[47]	giv[45]|new[47]	_	_
9-16	910-911	,	substance[45]	giv[45]	_	_
9-17	912-922	mechanical	substance[45]|abstract[48]	giv[45]|new[48]	_	_
9-18	923-929	damage	substance[45]|abstract[48]	giv[45]|new[48]	_	_
9-19	930-931	,	substance[45]	giv[45]	_	_
9-20	932-946	bacteriophages	substance[45]|object	giv[45]|new	ana	10-1
9-21	947-948	,	substance[45]	giv[45]	_	_
9-22	949-951	or	substance[45]	giv[45]	_	_
9-23	952-961	predators	substance[45]|animal	giv[45]|new	_	_
9-24	962-963	.	_	_	_	_

#Text=They are also more resistant to the immune system and antibiotics in a human or animal body .
10-1	964-968	They	object	giv	_	_
10-2	969-972	are	_	_	_	_
10-3	973-977	also	_	_	_	_
10-4	978-982	more	_	_	_	_
10-5	983-992	resistant	_	_	_	_
10-6	993-995	to	_	_	_	_
10-7	996-999	the	abstract[52]	new[52]	_	_
10-8	1000-1006	immune	abstract[52]	new[52]	_	_
10-9	1007-1013	system	abstract[52]	new[52]	_	_
10-10	1014-1017	and	_	_	_	_
10-11	1018-1029	antibiotics	substance[53]	new[53]	_	_
10-12	1030-1032	in	substance[53]	new[53]	_	_
10-13	1033-1034	a	substance[53]|object[54]	new[53]|new[54]	coref	21-7[104_54]
10-14	1035-1040	human	substance[53]|object[54]	new[53]|new[54]	_	_
10-15	1041-1043	or	substance[53]|object[54]	new[53]|new[54]	_	_
10-16	1044-1050	animal	substance[53]|object[54]	new[53]|new[54]	_	_
10-17	1051-1055	body	substance[53]|object[54]	new[53]|new[54]	_	_
10-18	1056-1057	.	_	_	_	_

#Text=The surface of the material is very quickly occupied by bacteria because the host products create a biofilm on the material that helps to bind the bacteria .
11-1	1058-1061	The	place[55]	new[55]	coref	27-9[0_55]
11-2	1062-1069	surface	place[55]	new[55]	_	_
11-3	1070-1072	of	place[55]	new[55]	_	_
11-4	1073-1076	the	place[55]|object[56]	new[55]|new[56]	coref	11-20[60_56]
11-5	1077-1085	material	place[55]|object[56]	new[55]|new[56]	_	_
11-6	1086-1088	is	_	_	_	_
11-7	1089-1093	very	_	_	_	_
11-8	1094-1101	quickly	_	_	_	_
11-9	1102-1110	occupied	_	_	_	_
11-10	1111-1113	by	_	_	_	_
11-11	1114-1122	bacteria	animal	giv	coref	11-26[61_0]
11-12	1123-1130	because	_	_	_	_
11-13	1131-1134	the	abstract[58]	giv[58]	coref	17-16[79_58]
11-14	1135-1139	host	abstract[58]	giv[58]	_	_
11-15	1140-1148	products	abstract[58]	giv[58]	_	_
11-16	1149-1155	create	_	_	_	_
11-17	1156-1157	a	substance[59]	giv[59]	coref	18-2[84_59]
11-18	1158-1165	biofilm	substance[59]	giv[59]	_	_
11-19	1166-1168	on	substance[59]	giv[59]	_	_
11-20	1169-1172	the	substance[59]|object[60]	giv[59]|giv[60]	_	_
11-21	1173-1181	material	substance[59]|object[60]	giv[59]|giv[60]	_	_
11-22	1182-1186	that	_	_	_	_
11-23	1187-1192	helps	_	_	_	_
11-24	1193-1195	to	_	_	_	_
11-25	1196-1200	bind	_	_	_	_
11-26	1201-1204	the	animal[61]	giv[61]	coref	17-6[76_61]
11-27	1205-1213	bacteria	animal[61]	giv[61]	_	_
11-28	1214-1215	.	_	_	_	_

#Text=This process takes place in five stages , as can be seen in
12-1	1216-1220	This	abstract[62]	new[62]	_	_
12-2	1221-1228	process	abstract[62]	new[62]	_	_
12-3	1229-1234	takes	_	_	_	_
12-4	1235-1240	place	_	_	_	_
12-5	1241-1243	in	_	_	_	_
12-6	1244-1248	five	abstract[63]	new[63]	_	_
12-7	1249-1255	stages	abstract[63]	new[63]	_	_
12-8	1256-1257	,	_	_	_	_
12-9	1258-1260	as	_	_	_	_
12-10	1261-1264	can	_	_	_	_
12-11	1265-1267	be	_	_	_	_
12-12	1268-1272	seen	_	_	_	_
12-13	1273-1275	in	_	_	_	_

#Text=Figure 3
13-1	1276-1282	Figure	abstract[64]	new[64]	_	_
13-2	1283-1284	3	abstract[64]	new[64]	_	_

#Text=.
14-1	1285-1286	.	_	_	_	_

#Text=Biofilms affect many medical applications and are a serious medical problem at the present time .
15-1	1287-1295	Biofilms	object	giv	ana	16-1
15-2	1296-1302	affect	_	_	_	_
15-3	1303-1307	many	abstract[66]	new[66]	_	_
15-4	1308-1315	medical	abstract[66]	new[66]	_	_
15-5	1316-1328	applications	abstract[66]	new[66]	_	_
15-6	1329-1332	and	_	_	_	_
15-7	1333-1336	are	_	_	_	_
15-8	1337-1338	a	abstract[67]	new[67]	_	_
15-9	1339-1346	serious	abstract[67]	new[67]	_	_
15-10	1347-1354	medical	abstract[67]	new[67]	_	_
15-11	1355-1362	problem	abstract[67]	new[67]	_	_
15-12	1363-1365	at	abstract[67]	new[67]	_	_
15-13	1366-1369	the	abstract[67]|time[68]	new[67]|new[68]	_	_
15-14	1370-1377	present	abstract[67]|time[68]	new[67]|new[68]	_	_
15-15	1378-1382	time	abstract[67]|time[68]	new[67]|new[68]	_	_
15-16	1383-1384	.	_	_	_	_

#Text=They are found , for example , in catheters , stents , contact lenses , and many other implants .
16-1	1385-1389	They	object	giv	coref	19-6
16-2	1390-1393	are	_	_	_	_
16-3	1394-1399	found	_	_	_	_
16-4	1400-1401	,	_	_	_	_
16-5	1402-1405	for	_	_	_	_
16-6	1406-1413	example	_	_	_	_
16-7	1414-1415	,	_	_	_	_
16-8	1416-1418	in	_	_	_	_
16-9	1419-1428	catheters	object	new	coref	23-5
16-10	1429-1430	,	_	_	_	_
16-11	1431-1437	stents	object	giv	_	_
16-12	1438-1439	,	_	_	_	_
16-13	1440-1447	contact	_	_	_	_
16-14	1448-1454	lenses	object	new	_	_
16-15	1455-1456	,	_	_	_	_
16-16	1457-1460	and	_	_	_	_
16-17	1461-1465	many	object[73]	new[73]	coref	21-1[102_73]
16-18	1466-1471	other	object[73]	new[73]	_	_
16-19	1472-1480	implants	object[73]	new[73]	_	_
16-20	1481-1482	.	_	_	_	_

#Text=Biomaterials at risk of attaching bacteria together with corresponding body fluids and major components of the host products for bacterial growth are classified in Table 1 .
17-1	1483-1495	Biomaterials	substance[74]	new[74]	_	_
17-2	1496-1498	at	substance[74]	new[74]	_	_
17-3	1499-1503	risk	substance[74]|abstract	new[74]|new	coref	18-11[87_0]
17-4	1504-1506	of	_	_	_	_
17-5	1507-1516	attaching	_	_	_	_
17-6	1517-1525	bacteria	animal[76]	giv[76]	_	_
17-7	1526-1534	together	animal[76]	giv[76]	_	_
17-8	1535-1539	with	animal[76]	giv[76]	_	_
17-9	1540-1553	corresponding	animal[76]|substance[77]	giv[76]|new[77]	_	_
17-10	1554-1558	body	animal[76]|substance[77]	giv[76]|new[77]	_	_
17-11	1559-1565	fluids	animal[76]|substance[77]	giv[76]|new[77]	_	_
17-12	1566-1569	and	animal[76]	giv[76]	_	_
17-13	1570-1575	major	animal[76]|abstract[78]	giv[76]|new[78]	_	_
17-14	1576-1586	components	animal[76]|abstract[78]	giv[76]|new[78]	_	_
17-15	1587-1589	of	animal[76]|abstract[78]	giv[76]|new[78]	_	_
17-16	1590-1593	the	animal[76]|abstract[78]|abstract[79]	giv[76]|new[78]|giv[79]	_	_
17-17	1594-1598	host	animal[76]|abstract[78]|abstract[79]	giv[76]|new[78]|giv[79]	_	_
17-18	1599-1607	products	animal[76]|abstract[78]|abstract[79]	giv[76]|new[78]|giv[79]	_	_
17-19	1608-1611	for	animal[76]|abstract[78]|abstract[79]	giv[76]|new[78]|giv[79]	_	_
17-20	1612-1621	bacterial	animal[76]|abstract[78]|abstract[79]|animal|abstract[81]	giv[76]|new[78]|giv[79]|new|giv[81]	_	_
17-21	1622-1628	growth	animal[76]|abstract[78]|abstract[79]|abstract[81]	giv[76]|new[78]|giv[79]|giv[81]	_	_
17-22	1629-1632	are	_	_	_	_
17-23	1633-1643	classified	_	_	_	_
17-24	1644-1646	in	_	_	_	_
17-25	1647-1652	Table	abstract	new	coref	24-1
17-26	1653-1654	1	quantity	new	_	_
17-27	1655-1656	.	_	_	_	_

#Text=The biofilm ’s high resistance to antibacterial agents results in a great risk of infection and therefore creates a very hazardous situation for patient health .
18-1	1657-1660	The	abstract[85]	giv[85]	coref	19-8[94_85]
18-2	1661-1668	biofilm	substance[84]|abstract[85]	giv[84]|giv[85]	coref	20-9[0_84]
18-3	1669-1671	’s	substance[84]|abstract[85]	giv[84]|giv[85]	_	_
18-4	1672-1676	high	abstract[85]	giv[85]	_	_
18-5	1677-1687	resistance	abstract[85]	giv[85]	_	_
18-6	1688-1690	to	abstract[85]	giv[85]	_	_
18-7	1691-1704	antibacterial	abstract[85]|substance[86]	giv[85]|new[86]	_	_
18-8	1705-1711	agents	abstract[85]|substance[86]	giv[85]|new[86]	_	_
18-9	1712-1719	results	_	_	_	_
18-10	1720-1722	in	_	_	_	_
18-11	1723-1724	a	abstract[87]	giv[87]	_	_
18-12	1725-1730	great	abstract[87]	giv[87]	_	_
18-13	1731-1735	risk	abstract[87]	giv[87]	_	_
18-14	1736-1738	of	abstract[87]	giv[87]	_	_
18-15	1739-1748	infection	abstract[87]|event	giv[87]|new	coref	25-18
18-16	1749-1752	and	_	_	_	_
18-17	1753-1762	therefore	_	_	_	_
18-18	1763-1770	creates	_	_	_	_
18-19	1771-1772	a	abstract[89]	new[89]	_	_
18-20	1773-1777	very	abstract[89]	new[89]	_	_
18-21	1778-1787	hazardous	abstract[89]	new[89]	_	_
18-22	1788-1797	situation	abstract[89]	new[89]	_	_
18-23	1798-1801	for	abstract[89]	new[89]	_	_
18-24	1802-1809	patient	abstract[89]|person|abstract[91]	new[89]|new|new[91]	coref|coref	21-8[103_0]|21-8[103_0]
18-25	1810-1816	health	abstract[89]|abstract[91]	new[89]|new[91]	_	_
18-26	1817-1818	.	_	_	_	_

#Text=Microbial cells that live in biofilms have greater resistance to antimicrobial substances than cells that live alone in planktonic form .
19-1	1819-1828	Microbial	object[92]	giv[92]	coref	19-14[0_92]
19-2	1829-1834	cells	object[92]	giv[92]	_	_
19-3	1835-1839	that	_	_	_	_
19-4	1840-1844	live	_	_	_	_
19-5	1845-1847	in	_	_	_	_
19-6	1848-1856	biofilms	substance	giv	coref	24-12
19-7	1857-1861	have	_	_	_	_
19-8	1862-1869	greater	abstract[94]	giv[94]	coref	20-3[98_94]
19-9	1870-1880	resistance	abstract[94]	giv[94]	_	_
19-10	1881-1883	to	abstract[94]	giv[94]	_	_
19-11	1884-1897	antimicrobial	abstract[94]|substance[95]	giv[94]|giv[95]	_	_
19-12	1898-1908	substances	abstract[94]|substance[95]	giv[94]|giv[95]	_	_
19-13	1909-1913	than	abstract[94]|substance[95]	giv[94]|giv[95]	_	_
19-14	1914-1919	cells	abstract[94]|substance[95]|object	giv[94]|giv[95]|giv	_	_
19-15	1920-1924	that	_	_	_	_
19-16	1925-1929	live	_	_	_	_
19-17	1930-1935	alone	_	_	_	_
19-18	1936-1938	in	_	_	_	_
19-19	1939-1949	planktonic	substance[97]	new[97]	_	_
19-20	1950-1954	form	substance[97]	new[97]	_	_
19-21	1955-1956	.	_	_	_	_

#Text=Due to this resistance , the treatment of biofilm infections is very difficult .
20-1	1957-1960	Due	_	_	_	_
20-2	1961-1963	to	_	_	_	_
20-3	1964-1968	this	abstract[98]	giv[98]	_	_
20-4	1969-1979	resistance	abstract[98]	giv[98]	_	_
20-5	1980-1981	,	_	_	_	_
20-6	1982-1985	the	event[99]	new[99]	coref	23-9[0_99]
20-7	1986-1995	treatment	event[99]	new[99]	_	_
20-8	1996-1998	of	event[99]	new[99]	_	_
20-9	1999-2006	biofilm	event[99]|substance|abstract[101]	new[99]|giv|giv[101]	coref|coref|coref|coref	24-9[116_101]|25-15|24-9[116_101]|25-15
20-10	2007-2017	infections	event[99]|abstract[101]	new[99]|giv[101]	_	_
20-11	2018-2020	is	_	_	_	_
20-12	2021-2025	very	_	_	_	_
20-13	2026-2035	difficult	_	_	_	_
20-14	2036-2037	.	_	_	_	_

#Text=Infected implants must be removed from the patient ’s body .
21-1	2038-2046	Infected	object[102]	giv[102]	coref	23-1[109_102]
21-2	2047-2055	implants	object[102]	giv[102]	_	_
21-3	2056-2060	must	_	_	_	_
21-4	2061-2063	be	_	_	_	_
21-5	2064-2071	removed	_	_	_	_
21-6	2072-2076	from	_	_	_	_
21-7	2077-2080	the	object[104]	giv[104]	_	_
21-8	2081-2088	patient	person[103]|object[104]	giv[103]|giv[104]	_	_
21-9	2089-2091	’s	person[103]|object[104]	giv[103]|giv[104]	_	_
21-10	2092-2096	body	object[104]	giv[104]	_	_
21-11	2097-2098	.	_	_	_	_

#Text=This procedure is usually expensive and dangerous for patients because surgical procedures can cause other complications .
22-1	2099-2103	This	event[105]	new[105]	_	_
22-2	2104-2113	procedure	event[105]	new[105]	_	_
22-3	2114-2116	is	_	_	_	_
22-4	2117-2124	usually	_	_	_	_
22-5	2125-2134	expensive	_	_	_	_
22-6	2135-2138	and	_	_	_	_
22-7	2139-2148	dangerous	_	_	_	_
22-8	2149-2152	for	_	_	_	_
22-9	2153-2161	patients	person	new	_	_
22-10	2162-2169	because	_	_	_	_
22-11	2170-2178	surgical	event[107]	new[107]	_	_
22-12	2179-2189	procedures	event[107]	new[107]	_	_
22-13	2190-2193	can	_	_	_	_
22-14	2194-2199	cause	_	_	_	_
22-15	2200-2205	other	abstract[108]	new[108]	_	_
22-16	2206-2219	complications	abstract[108]	new[108]	_	_
22-17	2220-2221	.	_	_	_	_

#Text=Millions of implants and catheters are used for treatment every year .
23-1	2222-2230	Millions	object[109]	giv[109]	coref	24-6[115_109]
23-2	2231-2233	of	object[109]	giv[109]	_	_
23-3	2234-2242	implants	object[109]	giv[109]	_	_
23-4	2243-2246	and	object[109]	giv[109]	_	_
23-5	2247-2256	catheters	object[109]|object	giv[109]|giv	_	_
23-6	2257-2260	are	_	_	_	_
23-7	2261-2265	used	_	_	_	_
23-8	2266-2269	for	_	_	_	_
23-9	2270-2279	treatment	event	giv	_	_
23-10	2280-2285	every	_	_	_	_
23-11	2286-2290	year	_	_	_	_
23-12	2291-2292	.	_	_	_	_

#Text=Table 2 shows examples of implants prone to the infections of biofilms .
24-1	2293-2298	Table	object|abstract[114]	giv|new[114]	_	_
24-2	2299-2300	2	abstract[113]|abstract[114]	new[113]|new[114]	_	_
24-3	2301-2306	shows	abstract[113]|abstract[114]	new[113]|new[114]	_	_
24-4	2307-2315	examples	abstract[114]	new[114]	_	_
24-5	2316-2318	of	abstract[114]	new[114]	_	_
24-6	2319-2327	implants	abstract[114]|object[115]	new[114]|giv[115]	_	_
24-7	2328-2333	prone	abstract[114]|object[115]	new[114]|giv[115]	_	_
24-8	2334-2336	to	_	_	_	_
24-9	2337-2340	the	abstract[116]	giv[116]	_	_
24-10	2341-2351	infections	abstract[116]	giv[116]	_	_
24-11	2352-2354	of	abstract[116]	giv[116]	_	_
24-12	2355-2363	biofilms	abstract[116]|substance	giv[116]|giv	_	_
24-13	2364-2365	.	_	_	_	_

#Text=For this reason , new materials are being developed to reduce the risk of biofilm formation and infection .
25-1	2366-2369	For	_	_	_	_
25-2	2370-2374	this	abstract[118]	new[118]	_	_
25-3	2375-2381	reason	abstract[118]	new[118]	_	_
25-4	2382-2383	,	_	_	_	_
25-5	2384-2387	new	object[119]	new[119]	coref	26-1[124_119]
25-6	2388-2397	materials	object[119]	new[119]	_	_
25-7	2398-2401	are	_	_	_	_
25-8	2402-2407	being	_	_	_	_
25-9	2408-2417	developed	_	_	_	_
25-10	2418-2420	to	_	_	_	_
25-11	2421-2427	reduce	_	_	_	_
25-12	2428-2431	the	abstract[120]	new[120]	_	_
25-13	2432-2436	risk	abstract[120]	new[120]	_	_
25-14	2437-2439	of	abstract[120]	new[120]	_	_
25-15	2440-2447	biofilm	abstract[120]|substance|abstract[122]	new[120]|giv|new[122]	_	_
25-16	2448-2457	formation	abstract[120]|abstract[122]	new[120]|new[122]	_	_
25-17	2458-2461	and	abstract[120]	new[120]	_	_
25-18	2462-2471	infection	abstract[120]|abstract	new[120]|giv	_	_
25-19	2472-2473	.	_	_	_	_

#Text=These materials are based on polymer composites or polymers with surfaces modified with an antimicrobial agent .
26-1	2474-2479	These	object[124]	giv[124]	_	_
26-2	2480-2489	materials	object[124]	giv[124]	_	_
26-3	2490-2493	are	_	_	_	_
26-4	2494-2499	based	_	_	_	_
26-5	2500-2502	on	_	_	_	_
26-6	2503-2510	polymer	person|object[126]	new|new[126]	_	_
26-7	2511-2521	composites	object[126]	new[126]	_	_
26-8	2522-2524	or	_	_	_	_
26-9	2525-2533	polymers	object	new	_	_
26-10	2534-2538	with	_	_	_	_
26-11	2539-2547	surfaces	place	new	_	_
26-12	2548-2556	modified	_	_	_	_
26-13	2557-2561	with	_	_	_	_
26-14	2562-2564	an	substance[129]	new[129]	_	_
26-15	2565-2578	antimicrobial	substance[129]	new[129]	_	_
26-16	2579-2584	agent	substance[129]	new[129]	_	_
26-17	2585-2586	.	_	_	_	_

#Text=In addition , other options based on physical surface properties such as surface roughening , or vice versa smooth surface , super hydrophobic , etc. should be considered .
27-1	2587-2589	In	_	_	_	_
27-2	2590-2598	addition	_	_	_	_
27-3	2599-2600	,	_	_	_	_
27-4	2601-2606	other	abstract[130]	new[130]	_	_
27-5	2607-2614	options	abstract[130]	new[130]	_	_
27-6	2615-2620	based	_	_	_	_
27-7	2621-2623	on	_	_	_	_
27-8	2624-2632	physical	abstract[132]	new[132]	_	_
27-9	2633-2640	surface	place|abstract[132]	giv|new[132]	coref	27-13
27-10	2641-2651	properties	abstract[132]	new[132]	_	_
27-11	2652-2656	such	abstract[132]	new[132]	_	_
27-12	2657-2659	as	abstract[132]	new[132]	_	_
27-13	2660-2667	surface	abstract[132]|place|abstract[134]	new[132]|giv|new[134]	coref|coref	27-18[135_0]|27-18[135_0]
27-14	2668-2678	roughening	abstract[132]|abstract[134]	new[132]|new[134]	_	_
27-15	2679-2680	,	abstract[132]	new[132]	_	_
27-16	2681-2683	or	abstract[132]	new[132]	_	_
27-17	2684-2688	vice	abstract[132]	new[132]	_	_
27-18	2689-2694	versa	abstract[132]|place[135]	new[132]|giv[135]	_	_
27-19	2695-2701	smooth	abstract[132]|place[135]	new[132]|giv[135]	_	_
27-20	2702-2709	surface	abstract[132]|place[135]	new[132]|giv[135]	_	_
27-21	2710-2711	,	abstract[132]	new[132]	_	_
27-22	2712-2717	super	abstract[132]|substance[136]	new[132]|new[136]	_	_
27-23	2718-2729	hydrophobic	abstract[132]|substance[136]	new[132]|new[136]	_	_
27-24	2730-2731	,	_	_	_	_
27-25	2732-2736	etc.	_	_	_	_
27-26	2737-2743	should	_	_	_	_
27-27	2744-2746	be	_	_	_	_
27-28	2747-2757	considered	_	_	_	_
27-29	2758-2759	.	_	_	_	_
